Aortic stenosis is the most frequent primary valve disease in Europe and North America, requiring surgical or transcatheter treatment as its prevalence is constantly increasing due to an aging population. Transcatheter aortic valve replacement (TAVR) has emerged as an alternative to surgery in patients with a prohibitive or high surgical risk. However, its indication has been recently extended in both European and American guidelines to patients with a lower surgical risk. The combination of new-generation devices with rapid improvement in operator experience and development of innovative procedural techniques has significantly reduced periprocedural complications, including those related to cerebral embolization of valvular and/or vascular debris. However, a periprocedural major disabling stroke remains a rare but important and troubling complication, leading to increased morbidity and mortality. On the other hand, most TAVR patients have been shown to suffer from silent cerebral embolic ischemic injury detected at diffusion-weighted magnetic resonance imaging (DW-MRI) with uncertain short- and long-term clinical relevance. Cerebral embolic protection devices (CEPDs) have been developed to minimize the risk of periprocedural stroke. Numerous trials have investigated the feasibility, safety, and efficacy of these devices, with a trend toward a reduction of total cerebral ischemic volume and major disabling stroke. In this chapter, factors supporting employment of a CEPD during TAVR will be discussed as will the results of the main clinical trials on this topic; in addition, an overview of the current available CEPDs approved for clinical and preclinical use will be presented.